Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management.

[1]  M. Chimenti,et al.  Complement, infection, and autoimmunity. , 2019, Current opinion in rheumatology.

[2]  John D Lambris,et al.  The Challenges and Promise of Complement Therapeutics for Ocular Diseases , 2019, Front. Immunol..

[3]  J. Andersen,et al.  Complement C4 Prevents Viral Infection through Capsid Inactivation , 2019, Cell host & microbe.

[4]  S. Fagerholm,et al.  Beta2-Integrins and Interacting Proteins in Leukocyte Trafficking, Immune Suppression, and Immunodeficiency Disease , 2019, Front. Immunol..

[5]  K. McKeage.  Ravulizumab: First Global Approval , 2019, Drugs.

[6]  G. Remuzzi,et al.  C3 glomerulopathy — understanding a rare complement-driven renal disease , 2019, Nature Reviews Nephrology.

[7]  M. Okrój,et al.  Complement Activation as a Helping Hand for Inflammophilic Pathogens and Cancer , 2019, Front. Immunol..

[8]  S. Zeerleder,et al.  Hereditary angioedema: Linking complement regulation to the coagulation system , 2018, Research and practice in thrombosis and haemostasis.

[9]  L. P. Van den Heuvel,et al.  The genetics of atypical hemolytic uremic syndrome , 2018, medizinische genetik.

[10]  O. Schueler‐Furman,et al.  Molecular pathogenesis of human CD59 deficiency , 2018, Neurology: Genetics.

[11]  B. Nilsson,et al.  Interpretation of Serological Complement Biomarkers in Disease , 2018, Front. Immunol..

[12]  Z. Prohászka,et al.  Complement analysis in the era of targeted therapeutics. , 2018, Molecular immunology.

[13]  K. Neuzil,et al.  Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. , 2018, The Lancet. Infectious diseases.

[14]  M. Laabei,et al.  Catch Me if You Can: Streptococcus pyogenes Complement Evasion Strategies , 2018, Journal of Innate Immunity.

[15]  Richard J. H. Smith,et al.  C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic , 2018, Mayo Clinic proceedings.

[16]  Ly-Mee Yu,et al.  Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function , 2018, Pediatrics.

[17]  J. Bueren,et al.  Leukocyte adhesion deficiency-I: A comprehensive review of all published cases. , 2018, The journal of allergy and clinical immunology. In practice.

[18]  Y. Modis,et al.  A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway , 2018, The Journal of allergy and clinical immunology.

[19]  T. Kinoshita.  Congenital Defects in the Expression of the Glycosylphosphatidylinositol-Anchored Complement Regulatory Proteins CD59 and Decay-Accelerating Factor. , 2018, Seminars in hematology.

[20]  R. Notaro,et al.  C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications. , 2018, Seminars in hematology.

[21]  V. Ferreira,et al.  Properdin: A multifaceted molecule involved in inflammation and diseases. , 2018, Molecular immunology.

[22]  A. Järvinen,et al.  Clinical features of patients with homozygous complement C4A or C4B deficiency , 2018, PloS one.

[23]  A. Nierhaus,et al.  A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab. , 2018, Vaccine.

[24]  A. Lotery,et al.  Genetics and genetic testing for age-related macular degeneration , 2018, Eye.

[25]  M. Kolev,et al.  Complement and the Regulation of T Cell Responses. , 2018, Annual review of immunology.

[26]  E. Volokhina,et al.  Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases , 2018, Front. Immunol..

[27]  G. Remuzzi,et al.  Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy , 2018, The Journal of Immunology.

[28]  S. Thiel,et al.  The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus , 2018, Front. Immunol..

[29]  M. Košnik,et al.  Functional Complement Analysis Can Predict Genetic Testing Results and Long-Term Outcome in Patients With Complement Deficiencies , 2018, Front. Immunol..

[30]  B. Zuraw.  Hereditary angioedema with normal C1 inhibitor: Four types and counting. , 2018, The Journal of allergy and clinical immunology.

[31]  D. Kavanagh,et al.  Diseases of complement dysregulation—an overview , 2018, Seminars in Immunopathology.

[32]  J. Casanova,et al.  The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies , 2017, Journal of Clinical Immunology.

[33]  Steven M. Holland,et al.  International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity , 2017, Journal of Clinical Immunology.

[34]  M. Kirschfink,et al.  A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma , 2017, Oncotarget.

[35]  Daniel Ricklin,et al.  Novel mechanisms and functions of complement , 2017, Nature Immunology.

[36]  S. Marshall,et al.  Genetic mannose binding lectin deficiency is associated with airway microbiota diversity and reduced exacerbation frequency in COPD , 2017, Thorax.

[37]  M. Bulsara,et al.  Undetectable Mannose Binding Lectin and Corticosteroids Increase Serious Infection Risk in Rheumatoid Arthritis. , 2017, The journal of allergy and clinical immunology. In practice.

[38]  P. Gipson,et al.  The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε. , 2017, Journal of the American Society of Nephrology : JASN.

[39]  D. Mevorach,et al.  Demyelination, strokes, and eculizumab: Lessons from the congenital CD59 gene mutations. , 2017, Molecular immunology.

[40]  D. Granoff,et al.  Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. , 2017, Blood.

[41]  J. Enghild,et al.  Analysis of Factor D Isoforms in Malpuech–Michels–Mingarelli–Carnevale Patients Highlights the Role of MASP-3 as a Maturase in the Alternative Pathway of Complement , 2017, The Journal of Immunology.

[42]  J. McElwee,et al.  CD55 Deficiency, Early‐Onset Protein‐Losing Enteropathy, and Thrombosis , 2017, The New England journal of medicine.

[43]  D. Geiger,et al.  Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy. , 2017, The New England journal of medicine.

[44]  D. Ricklin,et al.  Complement in clinical medicine: Clinical trials, case reports and therapy monitoring , 2017, Molecular immunology.

[45]  Michael H. Preuss,et al.  The association of mannose-binding lectin 2 polymorphisms with outcome in very low birth weight infants , 2017, PloS one.

[46]  T. Kinoshita,et al.  Paroxysmal nocturnal haemoglobinuria , 2017, Nature Reviews Disease Primers.

[47]  K. Skjoedt,et al.  A novel antihuman C3d monoclonal antibody with specificity to the C3d complement split product. , 2017, Journal of immunological methods.

[48]  A. D. den Hollander,et al.  The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment , 2017, Molecular immunology.

[49]  William H. Yang,et al.  Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor , 2017, The New England journal of medicine.

[50]  H. Cook,et al.  C3 glomerulopathy , 2017, F1000Research.

[51]  P. Beales,et al.  COLEC10 is mutated in 3MC patients and regulates early craniofacial development , 2017, PLoS genetics.

[52]  A. Rawat,et al.  Complement in autoimmune diseases. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[53]  A. Boldt,et al.  Association of a new FCN3 haplotype with high ficolin-3 levels in leprosy , 2017, PLoS neglected tropical diseases.

[54]  B. Tönshoff,et al.  Monitoring of complement activation biomarkers and eculizumab in complement‐mediated renal disorders , 2017, Clinical and experimental immunology.

[55]  J. Atkinson,et al.  Complement Dysregulation and Disease: Insights from Contemporary Genetics. , 2017, Annual review of pathology.

[56]  T. Langmann,et al.  Local complement activation in aqueous humor in patients with age-related macular degeneration , 2017, Eye.

[57]  M. Kolev,et al.  Keeping It All Going—Complement Meets Metabolism , 2017, Front. Immunol..

[58]  D. Mevorach,et al.  Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation , 2016, Annals of neurology.

[59]  John D Lambris,et al.  Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense , 2016, Immunological reviews.

[60]  M. Triggiani,et al.  International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency , 2016, Allergy.

[61]  H. Davies,et al.  Recommendations for Serogroup B Meningococcal Vaccine for Persons 10 Years and Older , 2016, Pediatrics.

[62]  J W Lee,et al.  Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry , 2016, Internal medicine journal.

[63]  P. Gál,et al.  MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked , 2016, Scientific Reports.

[64]  S. R. Córdoba.  Complement genetics and susceptibility to inflammatory disease. Lessons from genotype–phenotype correlations , 2016 .

[65]  J. Foley.  Examining coagulation-complement crosstalk: complement activation and thrombosis. , 2016, Thrombosis research.

[66]  L. Isaac,et al.  Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway , 2016, Front. Immunol..

[67]  Jennifer Holdaway,et al.  Mannose-binding lectin deficiency and predisposition to recurrent infection in adults , 2016, Journal of Clinical Pathology.

[68]  Yara T. E. Lechanteur,et al.  Nature Genetics Advance Online Publication , 2022 .

[69]  L. Truedsson.  Classical pathway deficiencies - A short analytical review. , 2015, Molecular immunology.

[70]  C. Bogdan,et al.  Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease , 2015, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[71]  Simon J. Clark,et al.  Age-related macular degeneration and the role of the complement system. , 2015, Molecular immunology.

[72]  M. Trendelenburg,et al.  Clinical presentation of human C1q deficiency: How much of a lupus? , 2015, Molecular immunology.

[73]  G. Remuzzi,et al.  Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015 , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[74]  V. Frémeaux-Bacchi,et al.  Complement System Part I – Molecular Mechanisms of Activation and Regulation , 2015, Front. Immunol..

[75]  M. Moll,et al.  Primary Ficolin-3 deficiency--Is it associated with increased susceptibility to infections? , 2015, Immunobiology.

[76]  J. Atkinson,et al.  Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. , 2015, Blood.

[77]  A. Boldt,et al.  MBL-associated serine proteases (MASPs) and infectious diseases , 2015, Molecular Immunology.

[78]  T. Craig,et al.  Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) , 2015, Expert review of clinical immunology.

[79]  P. Kralickova,et al.  Spectrum and Management of Complement Immunodeficiencies (Excluding Hereditary Angioedema) Across Europe , 2015, Journal of Clinical Immunology.

[80]  M. Cicardi,et al.  Pathophysiology of Hereditary Angioedema. , 2014, Pediatric allergy, immunology, and pulmonology.

[81]  R. Brodsky,et al.  Paroxysmal nocturnal hemoglobinuria. , 2014, Blood.

[82]  M. Kirschfink,et al.  Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. , 2014, Molecular immunology.

[83]  S. Perkins,et al.  New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3 , 2014, Bioscience reports.

[84]  F. Cosio,et al.  Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. , 2014, Journal of the American Society of Nephrology : JASN.

[85]  A. D. den Hollander,et al.  Impact of the Common Genetic Associations of Age-Related Macular Degeneration upon Systemic Complement Component C3d Levels , 2014, PloS one.

[86]  R. Klein,et al.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.

[87]  A. Bousvaros,et al.  2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[88]  P. O'kelly,et al.  C3 glomerulopathy: clinicopathologic features and predictors of outcome. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[89]  I. Heijnen,et al.  Anti-C1q Antibodies as a Follow-Up Marker in SLE Patients , 2013, PloS one.

[90]  L. Trouw,et al.  Autoantibodies against complement components and functional consequences. , 2013, Molecular immunology.

[91]  K. Bork.  Hereditary angioedema with normal C1 inhibitor. , 2013, Immunology and allergy clinics of North America.

[92]  M. Pickering,et al.  Dense Deposit Disease and C3 Glomerulopathy , 2013, Seminars in nephrology.

[93]  I. Winship,et al.  Deficiency in complement factor B. , 2013, The New England journal of medicine.

[94]  S. Ram,et al.  Meningococcal disease and the complement system , 2013, Virulence.

[95]  S. Thiel,et al.  Leprosy Association with Low MASP-2 Levels Generated by MASP2 Haplotypes and Polymorphisms Flanking MAp19 Exon 5 , 2013, PloS one.

[96]  T. Machnig,et al.  Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review. , 2013, Allergy and asthma proceedings.

[97]  M. Chimenti,et al.  Complement and autoimmunity , 2013, Immunologic Research.

[98]  A. Boldt,et al.  Association of L-Ficolin Levels and FCN2 Genotypes with Chronic Chagas Disease , 2013, PloS one.

[99]  John Hwa,et al.  Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome , 2013, Nature Genetics.

[100]  J. Moake,et al.  Assembly and Activation of Alternative Complement Components on Endothelial Cell-Anchored Ultra-Large Von Willebrand Factor Links Complement and Hemostasis-Thrombosis , 2013, PloS one.

[101]  A. Bakkaloğlu,et al.  DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. , 2013, Journal of the American Society of Nephrology : JASN.

[102]  G. Rijkers,et al.  Meningococcal Sepsis Complicating Eculizumab Treatment Despite Prior Vaccination , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[103]  Yong-Gang Yao,et al.  Genetic variants of complement genes Ficolin-2, Mannose-binding lectin and Complement factor H are associated with leprosy in Han Chinese from Southwest China , 2013, Human Genetics.

[104]  D. Gale,et al.  C3 glomerulonephritis and CFHR5 nephropathy. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[105]  John D Lambris,et al.  Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis. , 2013, Seminars in immunology.

[106]  J. Grünfeld,et al.  Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. , 2012, Kidney international.

[107]  E. Goicoechea de Jorge,et al.  A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. , 2012, Journal of the American Society of Nephrology : JASN.

[108]  B. Barres,et al.  The complement system: an unexpected role in synaptic pruning during development and disease. , 2012, Annual review of neuroscience.

[109]  J. Maciejewski,et al.  Paroxysmal nocturnal hemoglobinuria. , 2012, International journal of hematology.

[110]  M. Seidel,et al.  Mannan-binding lectin deficiency - Good news, bad news, doesn't matter? , 2012, Clinical immunology.

[111]  D. Hébert,et al.  Eculizumab and refractory membranoproliferative glomerulonephritis. , 2012, The New England journal of medicine.

[112]  Amos Etzioni,et al.  Leukocyte adhesion deficiencies , 2012, Annals of the New York Academy of Sciences.

[113]  T. van der Poll,et al.  Complement deficiency states and associated infections. , 2011, Molecular immunology.

[114]  S. Túlio,et al.  MASP2 gene polymorphism is associated with susceptibility to hepatitis C virus infection , 2011, Human Immunology.

[115]  G. Remuzzi,et al.  Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis , 2011, The Journal of Immunology.

[116]  S. Niemann,et al.  Variant G57E of Mannose Binding Lectin Associated with Protection against Tuberculosis Caused by Mycobacterium africanum but not by M. tuberculosis , 2011, PloS one.

[117]  R. Brodsky,et al.  Paroxysmal Nocturnal Hemoglobinuria from Bench to Bedside , 2011, Clinical and translational science.

[118]  I. Weitz.  Thrombosis in patients with paroxysmal nocturnal hemoglobinuria. , 2011, Seminars in thrombosis and hemostasis.

[119]  H. Peeters,et al.  Mutations in the lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome , 2011, Nature Genetics.

[120]  T. Walsh,et al.  MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes. , 2010, American journal of human genetics.

[121]  S. Ram,et al.  Infections of People with Complement Deficiencies and Patients Who Have Undergone Splenectomy , 2010, Clinical Microbiology Reviews.

[122]  S. Rodríguez de Córdoba,et al.  Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. , 2010, The Journal of clinical investigation.

[123]  Frcp,et al.  Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis , 2010, The Lancet.

[124]  R. Würzner,et al.  Complement in typical hemolytic uremic syndrome. , 2010, Seminars in thrombosis and hemostasis.

[125]  John D Lambris,et al.  Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.

[126]  William H. Yang,et al.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.

[127]  D. Lipsker,et al.  Cutaneous manifestations of complement deficiencies , 2010, Lupus.

[128]  G. Remuzzi,et al.  Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. , 2010, Seminars in nephrology.

[129]  T. Mészáros,et al.  C1-inhibitor autoantibodies in SLE , 2010, Lupus.

[130]  P. Garred,et al.  Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. , 2009, The New England journal of medicine.

[131]  P. Zipfel,et al.  Complement regulators and inhibitory proteins , 2009, Nature Reviews Immunology.

[132]  Francesco Saverio Tedesco,et al.  Complement in human diseases: Lessons from complement deficiencies. , 2009, Molecular immunology.

[133]  I. Brandslund,et al.  Plasma concentrations of complement split product C3d and immune complexes after procainamide induced production of antinuclear antibodies. , 2009, Acta medica Scandinavica.

[134]  M. Cicardi,et al.  C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. , 2009, Trends in molecular medicine.

[135]  M. Boermeester,et al.  Low Serum Mannose-Binding Lectin Level Increases the Risk of Death due to Pneumococcal Infection , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[136]  F. Rodríguez de Castro,et al.  Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. , 2008, The Journal of allergy and clinical immunology.

[137]  Martin Oppermann,et al.  Systemic Complement Activation in Age-Related Macular Degeneration , 2008, PloS one.

[138]  Robert B Sim,et al.  Comparative study of the human ficolins reveals unique features of Ficolin-3 (Hakata antigen). , 2008, Molecular immunology.

[139]  John D. Lambris,et al.  Complement evasion by human pathogens , 2008, Nature Reviews Microbiology.

[140]  T. Kuijpers,et al.  Low mannose‐binding lectin (MBL) levels in neonates with pneumonia and sepsis , 2007 .

[141]  M. Oppermann,et al.  Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. , 2007, Blood.

[142]  M. Daha,et al.  The clearance of apoptotic cells by complement. , 2007, Immunobiology.

[143]  H. Farkas,et al.  Recombinant human C1‐inhibitor in the treatment of acute angioedema attacks , 2007, Transfusion.

[144]  P. Ziakas,et al.  Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview , 2007, Journal of thrombosis and haemostasis : JTH.

[145]  C. Murdoch,et al.  Age-Dependent Association of Human Mannose-Binding Lectin Mutations With Susceptibility to Invasive Meningococcal Disease in Childhood , 2007, The Pediatric infectious disease journal.

[146]  B. Paul Morgan,et al.  Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome , 2007, Proceedings of the National Academy of Sciences.

[147]  L. Truedsson,et al.  Complement deficiencies and systemic lupus erythematosus , 2007, Autoimmunity.

[148]  C. Rodríguez-Gallego,et al.  Low clinical penetrance of mannose-binding lectin-associated serine protease 2 deficiency. , 2006, The Journal of allergy and clinical immunology.

[149]  R. Salomon,et al.  Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome , 2006, Journal of Medical Genetics.

[150]  R. Simon,et al.  Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. , 2006, Biochimica et biophysica acta.

[151]  P. Zipfel,et al.  Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). , 2006, Kidney International.

[152]  E. Reis,et al.  Clinical Aspects and Molecular Basis of Primary Deficiencies of Complement Component C3 and its Regulatory Proteins Factor I and Factor H , 2006, Scandinavian journal of immunology.

[153]  J. Thurman,et al.  The Central Role of the Alternative Complement Pathway in Human Disease1 , 2006, The Journal of Immunology.

[154]  M. Botto,et al.  Complement deficiencies in humans and animals: Links to autoimmunity , 2006, Autoimmunity.

[155]  A. Verloes,et al.  Michels syndrome, Carnevale syndrome, OSA syndrome, and Malpuech syndrome: Variable expression of a single disorder (3MC syndrome)? , 2005, American journal of medical genetics. Part A.

[156]  John D Lambris,et al.  Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. , 2005, Journal of the American Society of Nephrology : JASN.

[157]  G. Jönsson,et al.  Hereditary C2 Deficiency in Sweden: Frequent Occurrence of Invasive Infection, Atherosclerosis, and Rheumatic Disease , 2005, Medicine.

[158]  M. Carroll,et al.  A protective role for innate immunity in systemic lupus erythematosus , 2004, Nature Reviews Immunology.

[159]  Morten Dahl,et al.  A Population-based Study of Morbidity and Mortality in Mannose-binding Lectin Deficiency , 2004, The Journal of experimental medicine.

[160]  T. Mollnes,et al.  Modern Complement Analysis , 2003, Clinical Diagnostic Laboratory Immunology.

[161]  H. Käyhty,et al.  Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. , 2003, Vaccine.

[162]  L. Fugger,et al.  Inherited deficiency of mannan-binding lectin-associated serine protease 2. , 2003, The New England journal of medicine.

[163]  Y. Tokura,et al.  Lupus Erythematosus Associated with C1 Inhibitor Deficiency , 2002, The Journal of dermatology.

[164]  N. Gretz,et al.  Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: A long‐term follow‐up , 2001, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[165]  M. Hibberd,et al.  Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease , 1999, The Lancet.

[166]  M. Daha,et al.  Protection against meningococcal serogroup ACYW disease in complement‐deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine , 1998, Clinical and experimental immunology.

[167]  M. Oppermann,et al.  Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. , 1994, Immunology.

[168]  P. Densen,et al.  Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals. , 1993, The Journal of infectious diseases.

[169]  M. Oppermann,et al.  Complement activation in septic baboons detected by neoepitope‐specific assays for C3b/iC3b/C3c, C5a and the terminal C5b‐9 complement complex (TCC) , 1993, Clinical and experimental immunology.

[170]  K. Koretz,et al.  Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. , 1992, British Journal of Cancer.

[171]  P. Densen,et al.  C4B deficiency is not associated with meningitis or bacteremia with encapsulated bacteria. , 1992, The Journal of infectious diseases.

[172]  P. Densen,et al.  Infectious diseases associated with complement deficiencies , 1991, Clinical Microbiology Reviews.

[173]  T. Welch,et al.  C4B deficiency: a risk factor for bacteremia with encapsulated organisms. , 1990, The Journal of infectious diseases.

[174]  D. Overbosch,et al.  Complete and partial deficiencies of complement factor D in a Dutch family. , 1989, The Journal of clinical investigation.

[175]  R. Yasuda,et al.  Assay of complement activity in human serum using large unilamellar liposomes. , 1989, Journal of immunological methods.

[176]  A. Sjöholm,et al.  COMPLEMENT DEFICIENCIES IN PATIENTS OVER TEN YEARS OLD WITH MENINGOCOCCAL DISEASE DUE TO UNCOMMON SEROGROUPS , 1989, The Lancet.

[177]  P. Densen,et al.  Complement Deficiency States and Infection: Epidemiology, Pathogenesis and Consequences of Neisserial and Other Infections in an Immune Deficiency , 1984, Medicine.

[178]  B. Nilsson,et al.  Simplified assays of hemolytic activity of the classical and alternative complement pathways. , 1984, Journal of immunological methods.

[179]  I. Brandslund,et al.  Acute complement activation during an anaphylactoid reaction to blood transfusion and the disappearance rate of C3c and C3d from the circulation. , 1983, Journal of clinical & laboratory immunology.

[180]  U. Rother.  A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. , 1982, Journal of immunological methods.

[181]  N. Cooper,et al.  Development of an immunochemical test to assess C1 inactivator function in human serum and its use for the diagnosis of hereditary angioedema. , 1980, Clinical immunology and immunopathology.

[182]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[183]  E. Lebel,et al.  Post-eculizumab meningococcaemia in vaccinated patients. , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[184]  C. Walsh,et al.  Somatic Mosaicism and Neurological Diseases , 2016 .

[185]  U. Pannicke,et al.  Targeted therapy with eculizumab for inherited CD59 deficiency. , 2014, The New England journal of medicine.

[186]  A. Servais,et al.  C3 glomerulopathy. , 2013, Contributions to nephrology.

[187]  S. Thiel,et al.  Susceptibility to Leprosy is Associated with M-ficolin Polymorphisms , 2012, Journal of Clinical Immunology.

[188]  John D Lambris,et al.  Interactions between coagulation and complement—their role in inflammation , 2011, Seminars in Immunopathology.

[189]  L. Trouw,et al.  A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus. , 2005, Rheumatology.

[190]  A. Sjöholm,et al.  Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. , 2005, Journal of immunological methods.

[191]  B. Rovin,et al.  The intricate role of complement component C4 in human systemic lupus erythematosus. , 2004, Current directions in autoimmunity.

[192]  P. Taylor,et al.  Systemic lupus erythematosus, complement deficiency, and apoptosis. , 2000, Advances in immunology.

[193]  T. Mollnes.  Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex. , 1985, Complement.

[194]  K. Joiner,et al.  A study of optimal reaction conditions for an assay of the human alternative complement pathway. , 1983, American journal of clinical pathology.

[195]  H. Rapp,et al.  Molecular Basis of Complement Action , 1970 .